Company intelligence / Profile preview
Changchun BCHT Biotechnology Co.
Changchun, Jilin Province, Chinabchtpharm.com ↗
- Ownership
- Private
- Employees
- ~1241
- Development stage
- Other
01
Overview
The company has several approved products including Varicella Vaccine Live, Influenza Vaccine (Live, Nasal, Freeze-dried), and Herpes Zoster Vaccine Live. Their Varicella Vaccine has a leading market share in China. In January 2023, their zoster vaccine was approved, becoming the first zoster vaccine for people over 40 years old in China.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Prophylactic vaccinesLive attenuated vaccinesInactivated vaccinesMonoclonal antibodiesSmall molecule drugs
- Industry
- Biotech
02
Drug pipeline
23 assets22 more assets in the full pipeline.
03
Partnerships
Mucosis B.V. (strategic partnership for RSV vaccine development and Mimopath platform technology)IntravaccNIH (technical exchange and cooperation)
Beyond the preview
Go deeper on Changchun BCHT Biotechnology Co..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Changchun BCHT Biotechnology Co..